0001209191-21-070986.txt : 20211222 0001209191-21-070986.hdr.sgml : 20211222 20211222184210 ACCESSION NUMBER: 0001209191-21-070986 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211220 FILED AS OF DATE: 20211222 DATE AS OF CHANGE: 20211222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Suria Hamza CENTRAL INDEX KEY: 0001654495 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37985 FILM NUMBER: 211514373 MAIL ADDRESS: STREET 1: C/O ANAPTYSBIO, INC. STREET 2: 10421 PACIFIC CENTER COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANAPTYSBIO, INC CENTRAL INDEX KEY: 0001370053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203828755 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-362-6295 MAIL ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYSBIO INC DATE OF NAME CHANGE: 20080828 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC DATE OF NAME CHANGE: 20060724 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-20 0 0001370053 ANAPTYSBIO, INC ANAB 0001654495 Suria Hamza C/O ANAPTYSBIO, INC. 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 1 1 0 0 President, CEO Common Stock 2021-12-20 4 M 0 36645 1.12 A 105245 D Common Stock 2021-12-20 4 S 0 11915 34.8935 D 93330 D Common Stock 2021-12-20 4 S 0 19208 35.7547 D 74122 D Common Stock 2021-12-20 4 S 0 5522 36.4046 D 68600 D Employee Stock Option (Right to Buy) 1.12 2021-12-20 4 M 0 36645 0.00 D 2022-01-31 Common Stock 36645 0 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.26 to $36.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The stock option grant was issued on February 1, 2012, is fully vested and exercisable until its expiration date of January 31, 2022. In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly. /s/ Eric Loumeau, Attorney-in-Fact 2021-12-22